<DOC>
	<DOCNO>NCT00002542</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Hormone therapy use tamoxifen may fight breast cancer block uptake estrogen . Chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase III trial study effectiveness tamoxifen follow surgery chemotherapy treat woman stage I breast cancer high risk recurrence stage II stage III breast cancer .</brief_summary>
	<brief_title>Tamoxifen Treating Women With High-Risk Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare duration overall survival disease-free survival premenopausal woman operable , high risk node negative axillary node-positive breast cancer undergone complete surgical resection know disease mean total partial mastectomy , receive standard adjuvant chemotherapy cyclophosphamide , methotrexate , fluorouracil ( CMF ) , cyclophosphamide , epirubicin , fluorouracil ( CEF ) , doxorubicin cyclophosphamide ( AC ) follow either daily tamoxifen 5 year placebo . II . Compare short- long-term toxicity patient receive tamoxifen versus placebo . III . Monitor follicle-stimulating hormone , luteinizing hormone , estradiol level , determine whether overall survival disease-free survival affect hormonal menopausal status completion adjuvant chemotherapy tamoxifen placebo treatment patient . OUTLINE : This randomize , double blind study . Patients stratify adjuvant chemotherapy regimen ( cyclophosphamide , epirubicin , fluorouracil v cyclophosphamide , methotrexate , fluorouracil v cyclophosphamide doxorubicin ) , hormone receptor status ( ER and/or PR positive v ER PR negative ) , number positive node ( 1-3 v 4-9 v 10 ) , participate institution . Patients receive one three regimen adjuvant chemotherapy discretion investigator . Regimen A : Patients receive oral cyclophosphamide day 1-14 epirubicin IV fluorouracil IV day 1 8 . Courses repeat every 28 day total 6 course . Following chemotherapy , lumpectomy patient receive local radiotherapy daily 5 week . Regimen B : Patients receive oral cyclophosphamide day 1-14 cyclophosphamide IV day 1 8 , methotrexate day 1 8 , fluorouracil IV day 1 8 . Courses repeat every 28 day total 6 course . Concurrent follow chemotherapy , lumpectomy patient receive local radiotherapy daily 5 week . Regimen C : Patients receive doxorubicin IV cyclophosphamide IV every 21 day total 4 course . Following chemotherapy , lumpectomy patient receive local radiotherapy daily 5 week . Patients randomize receive either oral tamoxifen placebo daily 5 year , begin within 6 week completion chemotherapy . Treatment continue absence disease progression unacceptable toxicity . Patients follow survival . PROJECTED ACCRUAL : A total 800 patient accrue study 4 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Adenocarcinoma breast 1 histologically proven positive axillary node OR Adenocarcinoma breast negative axillary node adverse prognostic factor patient high risk recurrence node negative lesion characterize follow feature : Tumor least 1 cm Poorly differentiate , SBR grade III , MSBR grade V and/or lymphatic/vascular invasion Pathologic review experience breast pathologist recommend grade unspecified lymphatic/vascular invasion absent Disease consider potentially curable treat 1 following : Complete surgical removal breast plus axillary node dissection Partial surgical removal breast plus axillary node dissection , intention give breast irradiation follow completion adjuvant chemotherapy regimen Regional nodal chest wall irradiation prohibit strongly discourage No evidence residual tumor axilla follow dissection No microscopic evidence residual tumor resection margin follow total mastectomy Further excision highly recommend microscopic residual disease present partial mastectomy margin If excision undertaken , radiotherapy boost tumor bed require addition breast irradiation give follow protocol chemotherapy Disease clinically stag prior surgery T1T3a , N02 , M0 No clinical T4 disease , i.e . : No extension chest wall No edema ( include peau d'orange ) No skin ulceration No satellite skin nodule confine breast No inflammatory carcinoma Disease pathologically stag follow surgery TNM stage I , II , III ( T04 ; N02 ; M0 ) T4 allow dermal involvement pathology assessment No evidence metastatic disease beyond homolateral axillary node prechemotherapy chest xray , bone scan ( radiographs suspicious area ) , abdominal ultrasound ( require bilirubin , alkaline phosphatase , AST/ALT elevate ) Simultaneous bilateral breast carcinoma allow Complete tumor resection breast require Axillary dissection side must meet criterion side clinically nodepositive Axillary dissection second side optional axilla clinically negative time surgery side nodepositive Adjuvant chemotherapy must begin within 14 week initial pathologic diagnosis Hormone receptor status : Any receptor level allow ( value must available biochemical method use ; immunocytochemical assay permit ) PATIENT CHARACTERISTICS : Age : Not specify Sex : Female Menopausal status : Pre perimenopausal , i.e. , meet least 1 follow criterion : Normal menstruation Amenorrhea le 1 year ( 3 year patient age 52 ) Biochemical evidence ovarian function Hysterectomy without bilateral oophorectomy patient age 56 Premenopausal woman great age 50 start replacement hormone therapy amenorrhea eligible Performance status : ECOG 02 prior chemotherapy Hematopoietic : WBC least 3,000/mm3 Polymorphs band least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : ( unless abdominal ultrasound indicate liver metastasis ) Alkaline phosphatase great 2 time normal AST and/or ALT great 2 time normal Renal : Not specify Other : No history serious underlie medical illness psychiatric addictive disorder No second malignancy within 5 year except : Curatively treat nonmelanomatous skin cancer Curatively treat endometrium , colon , thyroid cancer carcinoma situ cervix No plan pregnancy 5year study period Fertile woman must use effective contraception ( oral contraception ) Accessible treatment followup PRIOR CONCURRENT THERAPY : Biologic therapy : Colonystimulating factor allow ( use must document ) Chemotherapy : No prior chemotherapy No concurrent cytotoxic therapy Endocrine therapy : Adjuvant tamoxifen ( 20 mg po daily ) allow 2 week adjuvant chemotherapy provide drug discontinue randomization No longterm prednisone hormone Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>